Ocular Therapeut (OCUL)

$9.70 -0.18 (-1.82%)
Market Cap 2.16B
Revenue (ttm) 51.95M
Net Income (ttm) -265.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -511.92%
Debt to Equity Ratio 0.12
Volume 1,427,300
Avg Vol 2,876,596
Day's Range N/A - N/A
Shares Out 218.96M
Stochastic %K 19%
Beta 0.88
Analysts Strong Sell
Price Target $26.73

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Address:
14 Crosby Drive, 3rd Floor, Bedford, United States
Tmoney85285
Tmoney85285 Jul. 14 at 8:09 PM
$OCUL another embarrassing day for the longs and a profitable day for me. all is right in the world again.
0 · Reply
Tmoney85285
Tmoney85285 Jul. 14 at 5:05 PM
$OCUL the long case, as summarized by phony Kyle. no case at all! how embarrassing.
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Jul. 14 at 4:28 PM
$OCUL Bounced off the 8 day EMA. I still see the week closing in the mid $10's.
2 · Reply
svertical1
svertical1 Jul. 14 at 4:17 PM
$OCUL Not difficult to understand….Billionszzzzz! https://grok.com/share/c2hhcmQtMw_61babff0-7d87-46db-a0e6-0638926dbc16
1 · Reply
MaxKlim
MaxKlim Jul. 14 at 1:39 PM
$OCUL
0 · Reply
moneybagged
moneybagged Jul. 14 at 11:48 AM
$OCUL $8
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Jul. 14 at 1:37 AM
$OCUL No room for juvenile posters. Moneybags can now play with teabags in grandma's cellar w/o clogging my feed.
1 · Reply
momos
momos Jul. 13 at 7:47 PM
$OCUL moneybagged sounds an awful lot like tmoney… time to block another spammer
1 · Reply
G101SPM
G101SPM Jul. 13 at 7:31 PM
#SHOWTIME International Society on Thrombosis and Haemostasis Congress (July 14) Scheduled to appear: $COAG Ophthalmology Innovation Source Retina Innovation Summit (July 14) Scheduled to appear: $OCUL, $OCGN, $OCS
0 · Reply
Tmoney85285
Tmoney85285 Jul. 13 at 5:50 PM
$OCUL moron is bad at numbers, full story at 11
2 · Reply
Latest News on OCUL
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 9, 2026, 4:05 PM EDT - 5 days ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Jul 1, 2026, 7:00 AM EDT - 13 days ago

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright

2026-06-18T15:20:29.000Z - 26 days ago

Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright

Ocular Therapeutix price target raised to $30 from $24 at Baird

2026-06-18T10:31:11.000Z - 26 days ago

Ocular Therapeutix price target raised to $30 from $24 at Baird

Ocular Therapeutix Transcript: Investor Day 2026

Jun 17, 2026, 2:00 PM EDT - 27 days ago

Ocular Therapeutix Transcript: Investor Day 2026

Ocular Therapeutix Press release: FY 2026

Jun 17, 2026, 2:00 PM EDT - 27 days ago

Ocular Therapeutix Press release: FY 2026

Ocular Therapeutix Slides: FY 2026

Jun 17, 2026, 2:00 PM EDT - 27 days ago

Ocular Therapeutix Slides: FY 2026

Ocular Therapeutix trading resumes

2026-06-17T13:15:09.000Z - 27 days ago

Ocular Therapeutix trading resumes

Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA

2026-06-17T12:56:42.000Z - 27 days ago

Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA

Ocular Therapeutix to resume trading at 9:15 am ET

2026-06-17T12:56:01.000Z - 27 days ago

Ocular Therapeutix to resume trading at 9:15 am ET

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Jun 17, 2026, 8:45 AM EDT - 27 days ago

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Ocular Therapeutix trading halted, news pending

2026-06-17T12:40:11.000Z - 27 days ago

Ocular Therapeutix trading halted, news pending

Ocular Therapeutix Transcript: AGM 2026

Jun 10, 2026, 8:30 AM EDT - 4 weeks ago

Ocular Therapeutix Transcript: AGM 2026

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Jun 4, 2026, 7:00 AM EDT - 5 weeks ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Jun 2, 2026, 7:00 AM EDT - 6 weeks ago

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular Therapeutix Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 2:30 PM EDT - 7 weeks ago

Ocular Therapeutix Transcript: Stifel 2026 Virtual Ophthalmology Forum

Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 6:40 PM EDT - 2 months ago

Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026

Ocular Therapeutix Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 2 months ago

Ocular Therapeutix Earnings Call Transcript: Q1 2026

Ocular Therapeutix Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 2 months ago

Ocular Therapeutix Earnings release: Q1 2026

Ocular Therapeutix Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 2 months ago

Ocular Therapeutix Quarterly report: Q1 2026

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

2026-05-05T11:59:32.000Z - 2 months ago

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

May 5, 2026, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Ocular Therapeutix Proxy statement: Proxy filing

Ocular Therapeutix Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Ocular Therapeutix Proxy statement: Proxy filing

Ocular Therapeutix enrolls first patient in Axpali trial

2026-04-29T13:00:19.000Z - 2 months ago

Ocular Therapeutix enrolls first patient in Axpali trial

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Apr 29, 2026, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Apr 28, 2026, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Ocular Therapeutix Transcript: HCW @ Home

Apr 27, 2026, 2:30 PM EDT - 2 months ago

Ocular Therapeutix Transcript: HCW @ Home

Ocular Therapeutix reports additional Axpaxli trial data

2026-04-13T11:22:45.000Z - 3 months ago

Ocular Therapeutix reports additional Axpaxli trial data

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Apr 13, 2026, 7:00 AM EDT - 3 months ago

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference

Mar 25, 2026, 9:30 AM EDT - 3 months ago

Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

Mar 20, 2026, 5:24 PM EDT - 4 months ago

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

EYPT

Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 9:00 AM EDT - 4 months ago

Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026

Ocular Therapeutix price target raised to $27 from $24 at BofA

2026-03-03T11:45:13.000Z - 4 months ago

Ocular Therapeutix price target raised to $27 from $24 at BofA

Ocular Therapeutix price target raised to $28 from $21 at Clear Street

2026-03-02T21:05:53.000Z - 4 months ago

Ocular Therapeutix price target raised to $28 from $21 at Clear Street

Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 4 months ago

Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference

Ocular Therapeutix Transcript: Study update

Mar 2, 2026, 7:30 AM EST - 4 months ago

Ocular Therapeutix Transcript: Study update

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 19, 2026, 10:41 AM EST - 5 months ago

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Ocular Therapeutix selloff brings attractive entry point, says Citizens

2026-02-17T19:15:34.000Z - 5 months ago

Ocular Therapeutix selloff brings attractive entry point, says Citizens

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

2026-02-17T15:55:17.000Z - 5 months ago

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

Ocular Therapeutix Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 5 months ago

Ocular Therapeutix Transcript: Study result

Ocular Therapeutix Press release: Study result

Feb 17, 2026, 8:00 AM EST - 5 months ago

Ocular Therapeutix Press release: Study result

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

2026-02-17T12:17:53.000Z - 5 months ago

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

Feb 17, 2026, 7:08 AM EST - 5 months ago

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

REGN

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Feb 13, 2026, 5:00 PM EST - 5 months ago

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2026, 4:01 PM EST - 5 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

2026-02-05T12:05:13.000Z - 5 months ago

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

Ocular Therapeutix Annual report: Q4 2025

Feb 5, 2026, 7:00 AM EST - 5 months ago

Ocular Therapeutix Annual report: Q4 2025

Ocular Therapeutix Earnings release: Q4 2025

Feb 5, 2026, 7:00 AM EST - 5 months ago

Ocular Therapeutix Earnings release: Q4 2025

Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer

2026-01-21T12:05:23.000Z - 6 months ago

Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer

MRK

Sanofi prepping higher bid for Ocular Therapeutix, IBD reports

2026-01-15T16:06:19.000Z - 6 months ago

Sanofi prepping higher bid for Ocular Therapeutix, IBD reports

SNY

Ocular Therapeutix Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:30 AM EST - 7 months ago

Ocular Therapeutix Transcript: Piper Sandler 37th Annual Healthcare Conference

Ocular Therapeutix Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 9:30 AM EST - 8 months ago

Ocular Therapeutix Transcript: Jefferies London Healthcare Conference 2025

Ocular Therapeutix Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 9 months ago

Ocular Therapeutix Earnings Call Transcript: Q3 2025

Ocular Therapeutix Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 9 months ago

Ocular Therapeutix Quarterly report: Q3 2025

Ocular Therapeutix Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 9 months ago

Ocular Therapeutix Earnings release: Q3 2025

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:05 AM EST - 9 months ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Nov 4, 2025, 7:00 AM EST - 9 months ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Oct 7, 2025, 7:00 AM EDT - 10 months ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix Transcript: Investor Day 2025

Sep 30, 2025, 2:00 PM EDT - 10 months ago

Ocular Therapeutix Transcript: Investor Day 2025

Ocular Therapeutix Press release: FY 2025

Sep 30, 2025, 2:00 PM EDT - 10 months ago

Ocular Therapeutix Press release: FY 2025

Ocular Therapeutix Slides: FY 2025

Sep 30, 2025, 2:00 PM EDT - 10 months ago

Ocular Therapeutix Slides: FY 2025

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 7:08 AM EDT - 10 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 30, 2025, 6:21 AM EDT - 10 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Ocular Therapeutix Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 12:50 PM EDT - 11 months ago

Ocular Therapeutix Transcript: Baird Global Healthcare Conference 2025

Ocular Therapeutix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 2:35 PM EDT - 11 months ago

Ocular Therapeutix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Ocular Therapeutix Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 2:00 PM EDT - 11 months ago

Ocular Therapeutix Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Ocular Therapeutix Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q2 2025

Ocular Therapeutix Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Quarterly report: Q2 2025

Ocular Therapeutix Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings release: Q2 2025

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 26, 2025, 1:54 PM EDT - 1 year ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Jun 16, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Ocular Therapeutix Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Stifel 2025 Virtual Ophthalmology Forum

Ocular Therapeutix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 4:30 PM EDT - 1 year ago

Ocular Therapeutix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Ocular Therapeutix Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 2:35 PM EDT - 1 year ago

Ocular Therapeutix Transcript: RBC Capital Markets Global Healthcare Conference 2025

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

May 14, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Ocular Therapeutix Transcript: Bank of America 2025 Healthcare Conference

May 13, 2025, 12:20 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Bank of America 2025 Healthcare Conference

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 9:00 AM EDT - 1 year ago

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference 2025

Ocular Therapeutix Quarterly report: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Quarterly report: Q1 2025

Ocular Therapeutix Earnings release: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings release: Q1 2025

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: 24th Annual Needham Virtual Healthcare Conference

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Ocular Therapeutix Slides: Corporate Presentation

Mar 27, 2025, 7:00 PM EDT - 1 year ago

Ocular Therapeutix Slides: Corporate Presentation

Ocular Therapeutix Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 10:00 AM EDT - 1 year ago

Ocular Therapeutix Transcript: Leerink Global Healthcare Conference 2025

Ocular Therapeutix Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:50 AM EST - 1 year ago

Ocular Therapeutix Transcript: TD Cowen 45th Annual Healthcare Conference

Ocular Therapeutix Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q4 2024

Ocular Therapeutix Annual report: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Annual report: Q4 2024

Ocular Therapeutix Earnings release: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings release: Q4 2024

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Feb 3, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Jan 14, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Therapeutix Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:15 PM EST - 1 year ago

Ocular Therapeutix Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 1:30 PM EST - 1 year ago

Ocular Therapeutix Transcript: Piper Sandler 36th Annual Healthcare Conference

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Ocular Therapeutix Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q3 2024

Ocular Therapeutix Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Quarterly report: Q3 2024

Ocular Therapeutix Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings release: Q3 2024

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Ocular Therapeutix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at September Retina Meetings

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Sep 4, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Ocular Therapeutix Earnings Call Transcript: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Earnings Call Transcript: Q2 2024

Ocular Therapeutix Quarterly report: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Quarterly report: Q2 2024

Ocular Therapeutix Earnings release: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Earnings release: Q2 2024

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 2 years ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 31, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 30, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 13, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Ocular Therapeutix Transcript: Investor Day 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: Investor Day 2024

Ocular Therapeutix Slides: FY 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Slides: FY 2024

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 4, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix Transcript: BofA Securities 2024 Health Care Conference

May 15, 2024, 6:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: BofA Securities 2024 Health Care Conference

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 1:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

Ocular Therapeutix Quarterly report: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Ocular Therapeutix Quarterly report: Q1 2024

Ocular Therapeutix Earnings release: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Ocular Therapeutix Earnings release: Q1 2024

Ocular Therapeutix Proxy statement: Proxy Filing

May 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2024, 8:16 PM EDT - 2 years ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

May 6, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

May 3, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

May 1, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Apr 18, 2024, 7:00 AM EDT - 2 years ago

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Tmoney85285
Tmoney85285 Jul. 14 at 8:09 PM
$OCUL another embarrassing day for the longs and a profitable day for me. all is right in the world again.
0 · Reply
Tmoney85285
Tmoney85285 Jul. 14 at 5:05 PM
$OCUL the long case, as summarized by phony Kyle. no case at all! how embarrassing.
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Jul. 14 at 4:28 PM
$OCUL Bounced off the 8 day EMA. I still see the week closing in the mid $10's.
2 · Reply
svertical1
svertical1 Jul. 14 at 4:17 PM
$OCUL Not difficult to understand….Billionszzzzz! https://grok.com/share/c2hhcmQtMw_61babff0-7d87-46db-a0e6-0638926dbc16
1 · Reply
MaxKlim
MaxKlim Jul. 14 at 1:39 PM
$OCUL
0 · Reply
moneybagged
moneybagged Jul. 14 at 11:48 AM
$OCUL $8
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Jul. 14 at 1:37 AM
$OCUL No room for juvenile posters. Moneybags can now play with teabags in grandma's cellar w/o clogging my feed.
1 · Reply
momos
momos Jul. 13 at 7:47 PM
$OCUL moneybagged sounds an awful lot like tmoney… time to block another spammer
1 · Reply
G101SPM
G101SPM Jul. 13 at 7:31 PM
#SHOWTIME International Society on Thrombosis and Haemostasis Congress (July 14) Scheduled to appear: $COAG Ophthalmology Innovation Source Retina Innovation Summit (July 14) Scheduled to appear: $OCUL, $OCGN, $OCS
0 · Reply
Tmoney85285
Tmoney85285 Jul. 13 at 5:50 PM
$OCUL moron is bad at numbers, full story at 11
2 · Reply
rizzato
rizzato Jul. 13 at 5:05 PM
$OCUL dreaming you and your friend tmoney toooo
0 · Reply
Tmoney85285
Tmoney85285 Jul. 13 at 4:35 PM
$OCUL embarrassing. he must be colorblind, which makes sense
0 · Reply
Tmoney85285
Tmoney85285 Jul. 13 at 3:52 PM
$OCUL $VKTX can’t hear you over all the money I’m making on these shorts- avg over 10 and 40.25 respectively with the recent run ups!
1 · Reply
ProfitForever
ProfitForever Jul. 13 at 3:12 PM
$BTDR my portfolio is centered around four stocks. $BTDR $PLUG $BE and $OCUL Holding and adding on the dips. I'm aggressive but not reckless. GL to all the Bulls!
1 · Reply
moneybagged
moneybagged Jul. 13 at 2:49 PM
$OCUL Ok lets take her down to $8.30 today🥴🤟
0 · Reply
Tmoney85285
Tmoney85285 Jul. 13 at 2:29 PM
$OCUL $VKTX us shorts over the past week! 10.50 and 42, freaking 42 last week?!? there are preschoolers who would know to short these pieces of crap! LMAO! more free money today!
3 · Reply
moneybagged
moneybagged Jul. 13 at 1:39 PM
$OCUL OUCH!!!! Short this Bitch!!!!$0
1 · Reply
moneybagged
moneybagged Jul. 13 at 1:23 PM
$OCUL 🥴🥴🥴🥴🥴🥴🥴
1 · Reply
MaxKlim
MaxKlim Jul. 13 at 1:08 PM
$OCUL
0 · Reply
Merlintrader
Merlintrader Jul. 11 at 1:42 PM
$OCUL Updated hub: full SOL-1 Phase 3 data at July retina meetings and H.C. Wainwright on July 22. Superiority over Eylea at Week 36; pre-NDA Q3 2026, AXPAXLI NDA (wet AMD) Q4 2026. https://www.merlintrader.com/ocular-therapeuthix-stock-hu/
1 · Reply
Aaronpell
Aaronpell Jul. 11 at 12:54 PM
$OCUL
1 · Reply
MaxKlim
MaxKlim Jul. 11 at 1:49 AM
$OCUL https://www.nasdaq.com/market-activity/stocks/ocul/short-interest
0 · Reply